🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Proteomic and Histological Analysis of Ligamentum Flavum in Lumbar Stenosis

Recruitingn/aAges 50 Years - 85 YearsAllFondazione Policlinico Universitario Agostino Gem…
NCT07026552 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Background Lumbar spinal stenosis (LSS) is a common condition characterized by spinal canal narrowing, often linked to ligamentum flavum hypertrophy (LFH) and degeneration. Fibrotic processes involving elastin and collagen alterations contribute to LF thickening and spinal instability. Despite progress, the molecular mechanisms underlying LFH remain unclear, necessitating targeted diagnostic and therapeutic strategies. Objective This study aims to analyze the proteomic and histological changes in LFH associated with LSS, correlating molecular signatures with imaging and surgical findings to identify potential therapeutic targets. Methods LF samples from LSS patients undergoing surgery will be analyzed using mass spectrometry-based proteomics and histology to identify biomarkers and molecular pathways. Correlations between imaging, intraoperative findings, and molecular profiles will be

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Radiological (CT and/or MRI) and clinical evidence of lumbar spinal stenosis (LSS). * Age range: 50-85 years. * Signed informed consent, medical records release form, and HIPAA authorization form (or equivalent according to local regulations), reviewed and signed by the patient or legally authorized representatives. Exclusion Criteria: * Pediatric population and individuals under 50 years of age. * Concomitant genetic musculoskeletal disorders. * History of trauma. * Spinal infections (spondylodiscitis, osteomyelitis, abscess, etc.). * Presence of spinal tumors or other neoplasms.
💊

What it tests

  • Not listed
📍

Where

1 site
Fondazione Policlinico Agostino Gemelli IRCSS
Rome, Italy
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy